NCT05198661 Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis Collection
| NCT ID | NCT05198661 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hospices Civils de Lyon |
| Condition | Paraneoplastic Neurological Syndromes or Autoimmune Encephalitis |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,500 participants |
| Start Date | 2022-08-02 |
| Primary Completion | 2032-08-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,500 participants in total. It began in 2022-08-02 with a primary completion date of 2032-08-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Numerous neurological disorders affecting the central and peripheral nervous system can be attributed to the immune system through multiple effector mechanisms. However, current treatments could be drastically improved by faster and more accurate diagnosis. The sample collection will benefit to patients with rare neuroimmune syndromes such as Autoimmune Encephalitis (AE) and Paraneoplastic Neurological Syndromes (PNS) leading to a better and early diagnosis, as well as treatment improvement.
Eligibility Criteria
Inclusion Criteria: * Patient with consent * Patient with well-characterized antibodies in serum or cerebrospinal fluid or not * Patient with neurological disorder compatible with PNS or auto-immune encephalitis Exclusion Criteria: * Refusal of consent * Patient under guardianship
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05198661 clinical trial?
This trial is open to participants of all sexes, studying Paraneoplastic Neurological Syndromes or Autoimmune Encephalitis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05198661 currently recruiting?
Yes, NCT05198661 is actively recruiting participants. Contact the research team at jerome.honnorat@chu-lyon.fr for enrollment information.
Where is the NCT05198661 trial being conducted?
This trial is being conducted at Pointe à Pitre, France, Aix-en-Provence, France, Amiens, France, Angers, France and 11 additional locations.
Who is sponsoring the NCT05198661 clinical trial?
NCT05198661 is sponsored by Hospices Civils de Lyon. The trial plans to enroll 3,500 participants.